Hypertension
Adult: 20 mg bid; increase to 40 mg bid after 2-4 wk as necessary. May also be given via IV/IM admin.
Indications and Dosage
Oral
Hypertension Adult: 20 mg bid; increase to 40 mg bid after 2-4 wk as necessary. May also be given via IV/IM admin.
|
Hepatic Impairment
Cirrhosis: Reduce dose or increase dosage interval. Severe hepatic impairment: A max of 20 mg bid is recommended.
|
Special Precautions
2nd or 3rd degree AV block. Patients predisposed to QT prolongation. May impair ability to drive or operate machinery.
|
Adverse Reactions
Sedation, fatigue, lightheadedness, dizziness, headache, dry mouth, GI disturbances, oedema, ventricular arrhythmias.
|
Drug Interactions
Hypotensive effects enhanced by diuretics and other antihypertensives.
Potentially Fatal: Increased risk of ventricular arrhythmias including torsade de pointes with antiarrhythmics or drugs that can cause hypokalaemia e.g. diuretics. |
Action
Description: Ketanserin is a serotonin antagonist that binds to peripheral serotonin-2 (5HT2) receptors resulting in inhibition of serotonin-induced vasoconstriction, bronchoconstriction and platelet aggregation.
Onset: 1-2 min (IV). Duration: 30-60 min (IV). Pharmacokinetics: Absorption: Rapidly absorbed from the GIT (oral); bioavailability: about 50%. Peak plasma concentrations after 30-120 min. Distribution: Protein-binding: 95%. May cross the placenta and some is present in breast milk. Metabolism: Hepatic. Excretion: Via urine (68% of an oral dose), via faeces (24%), mainly as metabolites. |
MIMS Class
|